STX-478 demonstrated in vivo efficacy and safety in preclinical models superior to clinically-relevant doses of alpelisib, a non-mutant selective PI3Kα inhibitor Efficacious in PI3Kα E542K
Scorpion Therapeutics Provides Clinical Program Updates for Its …
Scorpion has shown in Phase 1 monotherapy data that STX-478, an oral, once-daily, mutant-selective, allosteric PI3Kα inhibitor, demonstrated robust PI3Kα pathway inhibition as a …
Scorpion Therapeutics Announces First Patient Dosed in Phase 1/2 ...
STX-478 is designed to improve outcomes in patients harboring prevalent PI3Kα mutations in their tumors and has shown activity in both kinase and helical domain mutated tumors in …
STX-478, a Mutant-Selective, Allosteric PI3Kα Inhibitor Spares ...
Nov 1, 2023 · Here we describe STX-478, an allosteric PI3Kα inhibitor that selectively targets prevalent PI3Kα helical- and kinase-domain mutant tumors. STX-478 demonstrated robust …
First-in-Human Study of STX-478, a Mutant-Selective PI3Ka …
Study STX-478-101 is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 in participants with …
Lilly to acquire Scorpion Therapeutics' mutant-selective PI3Kα ...
2 days ago · The acquisition will expand Lilly's oncology pipeline with STX-478, the differentiated and potentially best-in-class, mutant-selective PI3Kα inhibitor currently in a Phase 1/2 clinical …
STX-478, a Mutant-Selective, Allosteric PI3Kα Inhibitor Spares ...
Nov 1, 2023 · Here we describe STX-478, an allosteric PI3Kα inhibitor that selectively targets prevalent PI3Kα helical- and kinase-domain mutant tumors. STX-478 demonstrated robust …
LBA27 First-in-human results of STX-478, a mutant-selective PI3Ka ...
STX-478 is an oral, allosteric, CNS-penetrant, mutant-selective PI3Kα inhibitor designed to improve efficacy while sparing WT toxicities. STX-478 led to robust efficacy without WT …
Abstract PO2-18-04: STX-478 is a potentially best-in-class mutant ...
May 2, 2024 · STX-478 is a potentially best-in-class mutant-selective PI3Kα inhibitor that demonstrates robust efficacy in ER+ breast cancer models as monotherapy and in …
Clinical Trials Using Mutant-selective PI3K-alpha H1047X Inhibitor STX-478
Study STX-478-101 is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 in participants with …
- Some results have been removed